| Feature Story: |
Medtronic and C.R. Bard Battle for Leading Position in 2018 US Drug-Coated Balloons Market |
|
The total U.S. market for peripheral vascular devices was valued at approximately $5.9 billion in 2017. Of the many segments that contribute to this market value, the drug-coated balloon (DCB) market is forecasted to be one of the fastest growing.
Drug-coated balloons have emerged as a promising technology for treating peripheral arterial disease. Since launching in late 2014, the superficial femoral artery (SFA) DCB market has increased rapidly in market value. In 2017, over 95% of DCBs sold in the U.S. were used in...
Read full press release online
|
|
|
 Edwards Lifesciences has won the latest round in a series of disputes with Boston Scientific over transcatheter aortic valve replacement (TAVR) patents. Irvine, CA-based Edwards said in a release that the United States Patent and Trademark Office has decided in its favor in an Inter Partes Review of Boston Scientifics’s patent – 8,992,608. The USPTO determined that all claims of the patent Boston Scientific asserted against Edwards are invalid.
“We are disappointed with the U.S. Patent Office decision on the BSC Haug ‘608 seal patent, and we plan to appeal,” a Boston Scientific spokesperson wrote in an email to MD+DI.
Edwards is known as the pioneer of TAVR and earned FDA approval for the Sapien Valve in 2011.
Boston Scientific has developed the Lotus valve, which garnered CE mark in 2013, but has yet to...
read more} |
|
|
|
 LivaNova PLC announced that it has entered into a definitive Stock and Asset Purchase Agreement (“Purchase Agreement”) to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation (“MicroPort”). LivaNova and MicroPort executed and delivered the Purchase Agreement, pursuant to the terms of a binding Letter of Intent, previously announced on November 20, 2017.
The announcement follows the successful completion of works council information and consultation requirements in France. The proposed transaction is subject to customary regulatory and other closing conditions. The transaction is expected to close in...
read more} |
|
 Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease (PAD), announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Münster, Germany, successfully treated the first three patients with the extended nosecone version of the next generation Pantheris Lumivascular atherectomy system (A400EX). This product is a line extension of the existing next generation platform, with a longer nosecone that enhances the plaque removal capacity of the device in addition to the feature improvements of the next generation of devices. This new device qualifies for commercial sale in the European Union (EU) under the existing CE Marking for Pantheris.
The extended nosecone increases the storage capacity of the Pantheris system by approximately 75%, which should translate to increased procedural efficiency, particularly in...
read more} |
|
|
|
|
